Díaz LPM, Mújica HMF, Olvera CA, González DJI, Montealegre RPA, Moreno SAA, González GN

Language: Spanish
References: 15
Page: 24-33
PDF size: 118.25 Kb.

ABSTRACT

Acute respiratory distress syndrome (ARDS) has an elevated mortality rate depending of original presenting illness, associated dysfunction of other systems and age. ARDS was first described in 1960s; initially the “A” in ARDS meant “adult” and it was used to differentiate this syndrome from the infantil form. Since 1994 the “A” stands for “acute”, because ARDS occurs in all age groups. Many predisposing factors are associated with the development of ARDS and it may be the pulmonary manifestation of a systemic process. ARDS is characterized by increased permeability of the aveolar-capillary membrane, diffuse alveolar damage, and the accumulation of proteinaceous pulmonary edema. The diagnostic criteria used to define ARDS, according to an American-European Consensus Conference are: a) PaO2/FIO2 = 200 mmHg; b) bilateral infiltrates on frontal chest radiograph; c) pulmonary arterial occlusion = 18 mmHg or no clinical evidence of lef atrial hypertension. There are no specific treatment that correct the pulmonar damage, however the use of appropriate strategies of mechanical ventilation and pharmacological therapies have led to a more favorable outcome.

REFERENCES

1. Ware LB, Matthay MA. The Acute Respiratory Distress Syndrome. NEJM 2000;342:1334-1349.

2. Meyer KC, McManus EJ, Maki DG. Overwhelming Pulmonary Blastomycosis associated with the Adult Respiratory Distress Syndrome. NEJM 1993;329:1231-1236.

3. Ognibene FP, Martin SE, Parker MM. Adult Respiratory Distress Syndrome in patients with severe neutropenia. NEJM 1986;315:547-551.

4. Krein PM, Sabatini PJB, Tinmouth W, Green FHY, Winston BW. Localization of Insulin-like Growth Factor-I in Lung Tissues of Patients with Fibroproliferative Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2003;167:83-90.

5. Hamacher J, Lucas R, Lijnen HR. Tumor Necrosis Factor-a and Angiostatin Are Mediators of Endothelial Cytotoxicity in Bronchoalveolar Lavages of Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2002; 166:651-656.

6. Bertozzi P, Astedt B, Zenzius L. Depressed bronchoalveolar urokinase activity in patients with Adult Respiratory Distress Syndrome. NEJM 1990;322:890-897.

7. Marshall R, Webb S, Bellingan GJ. Angiotensin Converting Enzyme Insertion/Deletion Polymorphism Is Associated with Susceptibility and Outcome in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2002;166:646-650.

8. Kollef MH, Schuster DP. The Acute Respiratory Distress Syndrome. NEJM 1995;332:27-37.

9. Massachusetts Medical Society. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and The Acute Respiratory Distress Syndrome. NEJM 2000;342:1301-1308.

10. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for The Adult Respiratory Distress Syndrome. NEJM 1993;328:399-405.

11. Bernard G, Luce JM, Sprung CL. High-dose corticosteroids in patients with The Adult Respiratory Distress Syndrome. NEJM 1987;317:1565-1569.

12. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319-323.

13. Duncan LA, Timothy WE. Acute respiratory distress syndrome. Lancet 1999;354:497-501.

14. Lanchou J, Corbel M, Michele T, Nowlla G, Boicot E, Theret N et al. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Critical Medical Care 2003;31(2):536-542.

15. Bernard GR, Artigas A, Brigham KL. The American- European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.